Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer

NCT00278343 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

74

Enrollment

NIH

Sponsor class

Conditions

Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer

Interventions

DRUG: cediranib maleate
OTHER: laboratory biomarker analysis

Sponsor

National Cancer Institute (NCI)